CD27 and neoplasm: We are currently working on expanding this repertoire of immune markers and developing panels that will include other immune inhibitory checkpoints (such as CTLA4, TIM-3, LAG-3, TIGIT, VISTA), immune stimulatory checkpoints (such as OX40, GITR, CD40, CD137, ICOS, CD27), innate immunity checkpoints (CD47), NK cell inhibitory receptors (KIRs, CD96), as well as panels to better elucidate myeloid lineage cells (macrophages, dendritic cells, myeloid derived suppressor cells) in the tumor microenvironment.